A report released today by Stifel Nicolaus about Clovis Oncology Inc (NASDAQ:CLVS) bumps the target price to $45.00
- Updated: September 25, 2016
Only yesterday Clovis Oncology Inc (NASDAQ:CLVS) traded -3.18% lower at $34.83. The company’s 50-day moving average is $24.12 and its 200-day moving average is $17.55. With the last stock price close up 111.60% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. Trade Volume was up over the average, with 8,169,572 shares of CLVS changing hands over the typical 2,669,770
Stifel Nicolaus raised the target price of Clovis Oncology Inc (NASDAQ:CLVS) to $45.00 stating a potential upside of 0.29%.
Previously on 8/24/2016, Mizuho Securities released a statement about Clovis Oncology Inc (NASDAQ:CLVS) upped the target price from $15.00 to $23.00 that indicated a possible downside of 0.00%.
Clovis Oncology Inc has 52 week low of $11.57 and a 52 week high of $109.18 and has a total market value of $0.
A total of 8 brokers have released a ratings update on CLVS. 2 firms rating the company a strong buy, zero analysts rating the company a buy, six brokerages rating the company a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average target price of $17.50.
About Clovis Oncology Inc (NASDAQ:CLVS)
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.